Deflazacort in Dysferlinopathies

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

April 30, 2008

Study Completion Date

September 30, 2008

Conditions
LGMD2BMiyoshi MyopathyDysferlinopathy
Interventions
DRUG

deflazacort

In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.

DRUG

placebo

Trial Locations (1)

80801

Friedrich-Baur-Institute, Dept. of Neurology, Ludwig-Maximilians-University of Munich, Munich

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER

NCT00527228 - Deflazacort in Dysferlinopathies | Biotech Hunter | Biotech Hunter